Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey
详细信息 查看全文
- 作者：Soner Uzun ; Aslı Bilgiç ; Temel ; Ayşe Akman Karakaş ; Erkan Ergü ; n ; Birgü ; l Ö ; zkesici ; Ali Haydar Eskiocak ; Ayşegü ; l Erat ; Nilay Uğurlu ; Berna Nazlım ; Saliha Koç ; Selen Bozkurt ; Ö ; zlem Dicle ; Erkan Alpsoy and Ertan Yılmaz
- 刊名：International Journal of Dermatology
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：55
- 期：12
- 页码：1362-1368
- 全文大小：92K
- ISSN：1365-4632
文摘
Pemphigus vulgaris (PV) is a severe, chronic, and potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes. Rituximab is a monoclonal anti-CD20 antibody which has been used increasingly in the therapy of PV.